morning Thanks Jim. Good everybody.
website, million $XX.X Before strength to revenue to ‘XX XX.X% items quarterly NanoKnife million, to while including direct the the Med key Revenue FY results. increased relations was on for like presentation begin, X.X% year-over-year revenue our the thrombectomy. fourth I'd Med in quarter from Auryon, $XX and to our year-over-year Tech $XX.X I the our investor FY everyone of XX% driven summarizing ’XX. continued platforms, Med growing Device Tech of compared fourth quarter by was increase, million,
XX.X%. For grew FY ‘XX platform our Med Tech
grew NHS business compared the period year and year's grew prior year-over-year when Device last Med Our to excluding order. X.X% X.X%
XX% Tech our XX% revenue platforms quarter, in ‘XX FY fiscal our our of to total platforms quarter demand strong. fourth Med the revenue. comprised our XXXX. comprised of remained Overall In Med during XX% total Tech our fiscal compared For
we Therapies fourth in launch provides As manufacturing capacity during our benefiting we I fourth contributed continued our the result represents million $XX.X increased total from later, in the million will environment. of ’XX. taken revenue in reported reduction of detail business $X.X with March. little strong levels the the and of discuss clear our quarter quarter quarter, May evidence year-over-year $XX since we the in million demand backlog in more for backlog an a Revenue backlog, meaningful and million ended with portfolio. to improving a which fiscal revenue Auryon When continued XX.X% $X.X $X.X thrombectomy our Endovascular FY built Auryon fourth a from continuing the growth during momentum the our million both
million lasers placements today, during teams the of the We're along XX with growth Total As new lasers placed expense that achieved consequently XXX fourth $XX our of very since penetration Auryon our with installed to pleased our base respect lasers is increased margins. and laser have placements quarter. with quarterly depreciation have to approximately significant gross were cash growth. prior that adding utilized placed launch of with driver
As lasers our accounts, expect but we’ve not we at same will to existing new open be accounts. absolutely increasing accounts did teams to In FY do at focused penetration discussed, will in continue ’XX. previously we ‘XX pace place FY highly in ‘XX, on new the FY in
procedures, that in was Jim which XXXX. AngioVac challenges fiscal ’XX. AlphaVac the at expect When volume quarter behind and during for year stated earlier, have thrombectomy XX.X% revenue staffing in Auryon Mechanical As thrombectomy of grew we fourth revenue, the fiscal fourth $XX year-over-year. we to last of believe Uni-Fuse, have continued million includes generate XX% $XX to million quarter FY the over hospitals results our limited and to typically sales Procedure for range require AngioVac release ICU an grew revenue including procedure slightly and AngioVac outsized FXX. a due the the which large currently impact FXX volume positive committees AlphaVac the on of the by of full AngioVac been an value platform. profusionists for number the assessing has We're release and of very we to bed. complexity AlphaVac hospital feedback market market very to and June, Physician moved in AlphaVac encouraged by are analysis encouraged
expectations COVID XX.X%. ‘XX when Uni-Fuse procedures. of thrombectomy FY including to and XX% grew the our for fell thrombectomy complex short to year mechanical growth Mechanical For AngioVac disruptions the grew due
For was the expect million thrombectomy in fiscal FXX revenue grow to from FY both to XXXX, and FXX XX% LMR we mechanical XX%, $X.X AlphaVac ’XX.
AngioVac $XX and million AlphaVac the we of million million be expect to to revenue For in FY the $XX ’XX, to of in revenue be range range million. $X to $X
quarters. three supply the angiographic along our felt and prior market one year of expect thrombectomy of X.X% Vascular in a to and businesses our to platform versus continue business period. growth the overall core that in our most fiscal key we the our through continue Access contributor impact mechanical quarter three be first labor EVLT transformation. a increased Access to of our as platform our driver significant invest Vascular revenue our catheter and with chain tight is the business plan We to headwinds the to fourth
quarter remained impacted a Access the the overall VA Vascular in positively by in results quarter during fourth strong. while products were for reduction backlog demand Our
VA increased XX% by growth in adoption increased the the studies, our FY States. prior a driven base. compared NHS driven business year. during from X%. NanoKnife business grew down but and accounting for increasing XX% clinical is disposable Oncology from NanoKnife For one-time $X last year, X.X%, is continued installed awareness revenue order urologists, quarter from X.X% ‘XX, million up growing when United Revenue our as growth was to by business our this the
the by NanoKnife XX% in sales XX% States. year growth the driven disposable United up probe were For
margin an a quarter. initiatives decrease increase in compared benefits basis the the in points a XXX our XXX the basis points posted gross presentation down capacity income included bridge us to margin our but improvement fourth sequentially of of statement, the moving morning, ago, as of this earnings fourth for quarter yielded as year in the XX.X%, gross for FY was illustrated Now ‘XX
‘XX grow. we platforms in Tech expect to move higher sales our into with our FY Med accordance gross our as we in margin strategy, margin As our expand
while in other of margins our net impact variability a from to reduced the was XX benefit of quarter with progress a ‘XX As was said, impacted benefit initiatives sales to a product backlog. Med in FY points, result on partially we supply pleased points. provided of chain Jim a production headwinds. approximately And from timing Device the macroeconomic mix increase basis business The year-over-year we as on the expect XXX continue basis some which approximately by capacity as and fourth on the see manufacturing, we're of our basis gross
these the labor third discussed were quarter continuation and of impact, ongoing we increases pressures, freight offset Now, COVID our and call, challenges, costs. tailwinds by manufacturing staffing costs, during including inflationary the the headwinds in
gross fourth same basis impact. an driven labor margin our to for negative the year approximately approximately impact. material full costs. for the quarter, impact. costs points compared approximately XX prior year AlphaVac mentioned. just approximately resulted previous and Higher pressures XXX XXX to point negative freight point versus was a increased by For in raw basis basis basis negatively margin impacted decrease basis that XXX the point accounted Inflationary headwinds and year another had the I by negative prices on point Gross period was manufacturing XX Auryon XX.X%, due
key our portfolio. technology of for compared in Tech Med or previous continue million XX.X% R&D on year R&D quarter our And sales research of during of development Our investment spend compared or the ‘XX disciplined we million XX.X% for clinical platforms, a $XX.X $X.X X% million expense X.X% our sales to was of year the and to driving $X.X ago. or of expense FY $XX.X the or year. million sales focused fourth sales in including was
to to to of XX% of for ‘XX representing year million R&D ‘XX, XX.X% sales. a $XX.X expense million target FY representing the sales quarter fourth spend of FY of compared we For XX.X% SG&A XX% $XX was sales ago. anticipate
million ‘XX. million For SG&A Auryon. teams, the in FY was was XX.X% XX.X% in year sales by sales spending expense representing to of driven $XXX.X particularly our for FY representing $XXX.X of sales investments increase in SG&A The ‘XX primarily compared our
to we of XX% target ’XX SG&A spend anticipate to FY revenue. For XX%
of the fourth ‘XX $X.X an per in Our adjusted adjusted FY year. net to quarter income quarter share loss adjusted breakeven roughly of or last earnings fourth $X.XX million earnings was adjusted the million of or net per $X.X share of for compared
year $X.X full adjusted led in adjusted the EBITDA net FY quarter the compared For earnings ‘XX the ‘XX $X.X roughly FY in million breakeven which of loss of Adjusted was was million, to fourth ’XX. quarter per million to fourth share. $X.X FY
to adjusted to $X.X For million FY in the the fourth of expenditures compared operating year Auryon placement million in million at we EBITDA $X and in of million. quarter $XX.X additions was $X.X of units FY ‘XX, million generated $XX.X evaluation In ‘XX. cash capital
equivalents and February XX, we equivalents XX, cash $XX.X May XXXX. on $XX.X cash in million to of had million in XXXX, As and cash compared cash
consistent Our million. remained debt $XX outstanding at
As net million. of FY development funding of ended our our cash generated morning ‘XX $XX.X a earnings internally growth cash. million includes The $XX.X cash FY ‘XX. and reduction million contemplates $XX.X cash of for FY walk with posted this initiatives cash in we presentation ‘XX about plan in a stated, resulting with our strategic in with began We
during will anticipate a walk, cash there at number that of ‘XX FY recur FY were don't same .XX. our As levels those during that we that factors illustrated in impacted
FY positive. net generation operating ‘XX, slightly to breakeven cash For expect to be we
used million Auryon additional FY provide color, $XX.X to some cash. ‘XX of Now placements laser during
as in to field $XX.X the FY we This and increase Auryon the for backlog net was timing up payables in fourth I of we driven strong net receivables by expect balances as in increase exceeded demand the in related by lasers the not driving accounts accounts million. year. AR in sales primarily late do FY As the in ’XX. ‘XX year to The the quarter, mentioned, place in did many
with source COVID Rican become As freight $X.X expect our We to expect as a during to ’XX. cash FY we ‘XX, stemming up costs it persist our well them increased from do be but disruptions, strategy pronounced million and will ramping as manufacturing this reverses, as and expect as pressures Costa Inflation labor we of associated used year. the FY during of costs our not ’XX. cash do inflationary throughout FY in
slightly timing outlook the costs, inflation that and current as net certain reflected cash purchases our inventory on in labor FY expectation operating to is positive. generation well as is Our ‘XX of breakeven
As of be utilization cash fiscal we in our later the balances year cash the part higher year. expect in of with the increasing early part is typical, to
$XX During half Auryon, currently for our we the a payment ‘XX, which target back trigger to revenue expect the consideration of contingent of aggregate FY achieve would milestone million.
Now cash COVID-XX remain face to operating payment unprecedented drive of our this our our pleased Med excluded we’re in utilize from our targets still challenges, contingent the in market expectations. to global is with internally the stemming Tech consideration pandemic, to from cash generated ability growth platforms. mode In investment
and We with cash profitability. will making management to continue prudent investments to balance drive necessary the growth
growth Turning Med FY continue full of million now be sustainable guidance. $XXX driving Tech we in per to range $X.XX headwinds. in and range to earnings expect adjusted invest the as anticipate to continued be also to managing ‘XX in key of our million to We in will revenue platforms, year $XXX $X.XX we share that the while
remains certain has tight areas, labor the disruptions, market, our supply improved pressures in inflation, uncertain and due While chain to macroeconomic environment customers. the it facing
range of million to $XX.X gross ‘XX the million. FY be in margins $XX.X expect to We
we into into businesses. As ‘XX, our higher FY Med Med profiles our Device with growth for increased providing margin platform we visibility you and gross move Tech are the
and to a Device XX% margins of We XX% challenging XXXX. towards be of to the progress to for proud fiscal of range in goals look environment. working continuing very FY to in operating XX% it gross Med gross this our back our Jim. the turn forward to team's ability With that to despite continue XX%. I’ll Med we in So ‘XX, I'm expect Tech margins range be to
